Novo Nordisk Could Benefit From Latest Fda Warning | Latest News RSS feed

Novo Nordisk Could Benefit From Latest Fda Warning - Latest News

Novo Nordisk Could Benefit From Latest FDA Warning

The FDA recently issued a warning about the linking of Fournier's gangrene with SGLT2 inhibitors used in the treatment of type-2 diabetes. Novo Nordisk claims that its GLP-1 analogues are better at ... read more

LIVE MARKETS-Who gains from greening the economy?

(1139 GMT) Between the U.S. "Green New ... could see a turn back toward value away from growth as the pain trade along the way as investors reassess the outlook even with policy easing." (Helen Reid) ... read more

Novo Nordisk nabs FDA nod for hemophilia A drug Esperoct but can’t launch until 2020

Novo Nordisk just added a new therapy to its declining hemophilia stable, but it won’t be able to reap the benefit until 2020. The FDA has greenlighted Esperoct ... The Roche drug has posted strong ... read more

Looking for another news?

No Added CV Risk for Oral Semaglutide in T2D

PIONEER 6 was the required cardiovascular safety study under current FDA policy ... was funded by Novo Nordisk. Source Reference: Hussain M, et al "Oral semaglutide and cardiovascular outcomes in ... read more

Novo Nordisk goes for broke on semaglutide heart data

Novo Nordisk and Eli Lilly are frequently fighting for market share in diabetes. In the relatively new class of GLP-1 agonists ... Trulicity's marketing edge could be substantial should the FDA ... read more

Oral Semaglutide Meets CV Safety Mark, Reduces Events in High-Risk T2D Patients

Novo ... Nordisk, liraglutide (Victoza) demonstrated a cardiovascular benefit (superiority) in the LEADER trial in 2016; that trial randomized 9340 patients and lasted 3.8 years. PIONEER 6 had 3183 ... read more

Novo Nordisk Insulin Fails to Win FDA’s Backing

Novo Nordisk A/S had ... Bernstein & Co. in New York, said in a report today. “The last thing FDA wants is to approve a new drug that could potentially run into a safety issue years later, especially ... read more

Novo Nordisk: Solid Performance Marred By Currency Fluctuations

Novo Nordisk should be able to continue some growth with its new oral semaglutide product that will be submitted for FDA approval within a few weeks. North America saw a sales decline, which could be ... read more

Does Novo Nordisk's New Diabetes Drug Spell Doom for MannKind Corp?

Anonymous That could spell trouble for MannKind as one of the benefits touted ... which is Novo Nordisk's current fastest-acting insulin, starts 40 to 50 minutes after being injected. We don't yet ... read more

Novo Nordisk Seeks Oral Semaglutide Approval, CV Indications on New Drug and Injectable

Novo Nordisk today filed for FDA approval of oral semaglutide, which would be the first glucagon-like peptide-1 (GLP-1) receptor agonist in a pill form. The drug maker also filed for a new ... read more

Novo's fast-launching Ozempic puts Lilly on notice—and its GLP-1 pill is on its way

Novo Nordisk has been fighting head-to-head with Eli Lilly ... And with its oral version of semaglutide at the FDA for review, another growth boost could be on its way. Rather than losing share to ... read more

Dapagliflozin Boosts Renal Function in T2D

In 2018, the FDA issued a warning letter mandating new labeling for SGLT2 inhibitors due to reported ... Mosenzon reported financial relationships with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk, ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us